Evolution of the Average Target: Gilead Sciences, Inc.

Evolution of the Average Target - Gilead Sciences, Inc.

Evolution of the Target Price: Gilead Sciences, Inc.

Evolution of the Target Price - Gilead Sciences, Inc.

Changes in Analyst Recommendations: Gilead Sciences, Inc.

7e1eb9d35954bab32514.8222sS76jXjOWl0UjvPkXf_UwNJfmXmNe75Ln9Xl8vk.mFnc8njDoCmvMhZMzYGNHrentOEM7jLICe070Y-wg5iCJ9_cZp3dH5wREA~4f7ebb595913bfc2745641399e7b32ae
21/10 Gilead's Biktarvy Pricing Impact Likely Manageable, RBC Says MT
15/10 Goldman Sachs Adjusts Price Target on Gilead Sciences to $142 From $135 MT
12/10 Gilead Sciences' Yeztugo Survey Supports Long-Term Growth Outlook, BofA Says MT
12/10 BofA Securities Adjusts Gilead Sciences Price Target to $168 From $162, Maintains Buy Rating MT
08/10 RBC Lifts Price Target on Gilead Sciences to $126 From $123, Keeps Sector Perform Rating MT
07/10 Morgan Stanley Adjusts Price Target on Gilead Sciences to $163 From $165 MT
07/10 JPMorgan Adjusts Price Target on Gilead Sciences to $170 From $160 MT
02/10 Legend Biotech Faces Pressure From Rivals Ahead of Key FDA Decision, UBS Says MT
10/09 HSBC Adjusts Price Target on Gilead Sciences to $175 From $155, Keeps Buy Rating MT
05/08 Gilead Sciences Delivers 'Plenty' to Like in Q2, RBC Says MT
05/08 Leerink Partners Adjusts Price Target on Gilead Sciences to $130 From $126 MT
05/08 Goldman Sachs Adjusts Price Target on Gilead Sciences to $135 From $130 MT
05/08 RBC Capital Adjusts Gilead Sciences Price Target to $123 From $120, Maintains Sector Perform Rating MT
04/08 Merck's Weekly HIV Treatment Pipeline 'Interesting,' UBS Says MT
28/07 Barclays Adjusts Gilead Sciences Price Target to $145 From $155, Maintains Equalweight Rating MT
23/07 Leerink Partners Adjusts Gilead Sciences Price Target to $126 From $127, Maintains Market Perform Rating MT
21/07 Gilead Sciences Shares Fall After Downgrade From Leerink Partners MT
21/07 Analyst recommendations: Gilead, Salesforce, Goldman Sachs, Carvana, Crowdstrike… Zonebourse
21/07 Leerink Partners Downgrades Gilead Sciences to Market Perform From Outperform, Adjusts PT to $127 From $146 MT
08/07 Biopharma Companies' Second-Half Performance to be Largely Driven by Fundamentals, Morgan Stanley Says MT
08/07 Morgan Stanley Adjusts Price Target Gilead Sciences to $166 From $168, Maintains Overweight Rating MT
07/07 Truist Securities Adjusts Gilead Sciences Price Target to $156 From $157 MT
07/07 RBC Capital Adjusts Gilead Sciences Price Target to $120 From $122, Maintains Sector Perform Rating MT
06/07 Analyst recommendations: Chubb, Delta Air Lines, Pfizer, AMD, Dow… Zonebourse
06/07 HSBC Upgrades Gilead Sciences to Buy From Hold, Adjusts Price Target to $155 From $133 MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+4.56%
+5.91%
-0.3%
-1.29%
+9.97%
-3.4%
+22.47%
-9.69%
+2.66%
Average +3.43%
Weighted average by Cap. +3.76%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
156.04USD
Average target price
160.19USD
Spread / Average Target
+2.66%
High Price Target
185.00USD
Spread / Highest target
+18.56%
Low Price Target
126.00USD
Spread / Lowest Target
-19.25%

Analyst Consensus Detail

Analyst consensus - Gilead Sciences, Inc.

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Gilead Sciences, Inc.
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Gilead Sciences, Inc.
  1. Stock Market
  2. Stocks
  3. GILD Stock
  4. GILD Stock
  5. Consensus Gilead Sciences, Inc.